Christina Zhang

Christina has over 30 years of practice experience, gained through private practice and in–house experience in the US and China. Christina represents clients and investment funds in cross border transactions, especially in life sciences and high tech industries. She has represented clients in their financings, licensing and partnership transactions, joint ventures, acquisitions and divestitures, manufacturing, distribution and marketing activities in China and US. 

Prior to joining the firm, Christina served as vice president and Asia Pacific general counsel for the Power Solutions Business of Johnson Controls Inc. Prior to joining Johnson Controls, Christina spent ten years in the life sciences industry, first as in-house counsel for Merck & Co. at its global headquarters in New Jersey, supporting Merck’s various operations around the world, and then as Wyeth's chief counsel in China, supporting Wyeth's infant formula and pharmaceutical business in China.

Christina started her legal career with Paul, Weiss, Rifkind, Wharton & Garrison in New York, working on various financing, securities and M&A transactions, and other general corporate matters in the US, as well as foreign direct investments, acquisitions, and joint venture projects in China.

Christina is a ranked lawyer for life sciences practice in China by Chambers and Partners for four consecutive years from 2021 to 2024. A client commented that “she is a very smart, practical and solution-oriented attorney..." and "very knowledgeable of all aspects of the life science business and is the go-to person for biotech matters in China." Christina is also recognized as a “Leading Individual” lawyer for Life Sciences and Healthcare practice in China by The Legal 500 Asia Pacific (2022 to 2024) and a “Notable Practitioner and Women Leader” for Private Equity practice in China - Foreign Firm by IFLR1000 Asia Pacific Rankings (2023). She is named by China Business Law Journal as one of the China practice “A-List Lawyers” of foreign law firms for four consecutive years from 2019 to 2022 as well as one of the “Growth Drivers” in 2023-2024